CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The T2EVOLVE project focuses on enhancing engineered T cell therapies for cancer treatment. By addressing challenges in safety, efficacy, and production, the project aims to accelerate the development and implementation of these innovative therapies in clinical practice.
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer.
Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use…
KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
France, Boulogne Billancourt
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
